169 related articles for article (PubMed ID: 10458251)
1. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.
Marshall JL; Hawkins MJ; Tsang KY; Richmond E; Pedicano JE; Zhu MZ; Schlom J
J Clin Oncol; 1999 Jan; 17(1):332-7. PubMed ID: 10458251
[TBL] [Abstract][Full Text] [Related]
2. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.
Zhu MZ; Marshall J; Cole D; Schlom J; Tsang KY
Clin Cancer Res; 2000 Jan; 6(1):24-33. PubMed ID: 10656428
[TBL] [Abstract][Full Text] [Related]
3. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
[TBL] [Abstract][Full Text] [Related]
4. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
Marshall JL; Hoyer RJ; Toomey MA; Faraguna K; Chang P; Richmond E; Pedicano JE; Gehan E; Peck RA; Arlen P; Tsang KY; Schlom J
J Clin Oncol; 2000 Dec; 18(23):3964-73. PubMed ID: 11099326
[TBL] [Abstract][Full Text] [Related]
5. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
Hodge JW; McLaughlin JP; Kantor JA; Schlom J
Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
[TBL] [Abstract][Full Text] [Related]
6. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
von Mehren M; Arlen P; Tsang KY; Rogatko A; Meropol N; Cooper HS; Davey M; McLaughlin S; Schlom J; Weiner LM
Clin Cancer Res; 2000 Jun; 6(6):2219-28. PubMed ID: 10873071
[TBL] [Abstract][Full Text] [Related]
8. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.
Hörig H; Lee DS; Conkright W; Divito J; Hasson H; LaMare M; Rivera A; Park D; Tine J; Guito K; Tsang KW; Schlom J; Kaufman HL
Cancer Immunol Immunother; 2000 Nov; 49(9):504-14. PubMed ID: 11092617
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
12. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
13. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.
Tsang KY; Zaremba S; Nieroda CA; Zhu MZ; Hamilton JM; Schlom J
J Natl Cancer Inst; 1995 Jul; 87(13):982-90. PubMed ID: 7629885
[TBL] [Abstract][Full Text] [Related]
14. Characterization of antigen-specific immune responses induced by canarypox virus vaccines.
Bos R; van Duikeren S; van Hall T; Lauwen MM; Parrington M; Berinstein NL; McNeil B; Melief CJ; Verbeek JS; van der Burg SH; Offringa R
J Immunol; 2007 Nov; 179(9):6115-22. PubMed ID: 17947686
[TBL] [Abstract][Full Text] [Related]
15. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
16. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
17. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine.
Huang Y; Fayad R; Smock A; Ullrich AM; Qiao L
Cancer Res; 2005 Aug; 65(15):6990-9. PubMed ID: 16061685
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
Alves PM; Viatte S; Fagerberg T; Michielin O; Bricard G; Bouzourene H; Vuilleumier H; Kruger T; Givel JC; Lévy F; Speiser DE; Cerottini JC; Romero P
Cancer Immunol Immunother; 2007 Nov; 56(11):1795-805. PubMed ID: 17447064
[TBL] [Abstract][Full Text] [Related]
19. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
20. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
